⌘K
Loading ticker…
Biogen Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Biogen Inc. Common Stock (BIIB) has a 3-month relative strength percentile of 62 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 60. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 3.2%, relative volume 2.15×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
62 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
BIIB is in a stage 2 uptrend, week 9. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 11.9% / 22.6%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
BIIB is held by 17 ETFs as of Mar 2026. Top owner: VTI at 0.04% weight, $853M notional. Top 3 carry $2.1B.
Top 10 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.04% | $853M |
| VOOVanguard S&P 500 ETF | 0.05% | $684M |
| VOVanguard Mid-Cap ETF | 0.29% | $581M |
| IVViShares Core S&P 500 ETF | 0.05% | $346M |
| SPYState Street SPDR S&P 500 ETF | 0.05% | $315M |
| VTVVanguard Value ETF | 0.11% | $249M |
| XLVState Street Health Care Select Sector SPDR ETF | 0.51% | $196M |
| IWRiShares Russell Midcap ETF | 0.21% | $102M |
| XBIState Street SPDR S&P Biotech ETF | 1.10% | $82M |
| IWDiShares Russell 1000 Value ETF | 0.09% | $62M |
Showing 10 of 17 ETF owners.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BIIB Jan avg: -0.82% median: -1.23% win: 50% σ: 5.30% n: 4 2022-04-12 → 2026-05-29 | BIIB Feb avg: -3.75% median: -4.81% win: 25% σ: 7.96% n: 4 2022-04-12 → 2026-05-29 | BIIB Mar avg: -1.16% median: -1.62% win: 25% σ: 3.19% n: 4 2022-04-12 → 2026-05-29 | BIIB Apr avg: -0.15% median: -0.38% win: 40% σ: 7.65% n: 5 2022-04-12 → 2026-05-29 | BIIB May avg: 1.86% median: 3.55% win: 60% σ: 4.71% n: 5 2022-04-12 → 2026-05-29 | BIIB Jun avg: -0.53% median: -0.63% win: 50% σ: 3.55% n: 4 2022-04-12 → 2026-05-29 (current) | BIIB Jul avg: -1.45% median: -1.61% win: 50% σ: 6.22% n: 4 2022-04-12 → 2026-05-29 | BIIB Aug avg: -2.71% median: -2.50% win: 25% σ: 5.22% n: 4 2022-04-12 → 2026-05-29 | BIIB Sep avg: 8.35% median: 1.04% win: 50% σ: 19.53% n: 4 2022-04-12 → 2026-05-29 | BIIB Oct avg: -0.38% median: -0.71% win: 50% σ: 10.04% n: 4 2022-04-12 → 2026-05-29 | BIIB Nov avg: 4.14% median: 3.10% win: 50% σ: 11.20% n: 4 2022-04-12 → 2026-05-29 | BIIB Dec avg: -1.71% median: -4.08% win: 25% σ: 8.55% n: 4 2022-04-12 → 2026-05-29 |